Health

Eptinezumab was found to reduce the severity and frequency of migraine days

Eptinezumab is an FDA-approved calcitonin gene-related peptide antagonist for the prophylactic treatment of migraine.

According to the results of the PROMISE-2 study, treatment with Eptinezumab (Vyepti) was observed to reduce the number of days of migraine and the monthly severity and frequency of episodes compared to placebo. headache..

Chronic migraine (CM) has a high prevalence and is associated with poor quality of life and can affect work, school, and the social life of the patient. People diagnosed with this condition may experience frequent headaches of 15 days or more per month, at least eight of which meet the international migraine headache disorder classification criteria. CM also involves higher levels of disability, comorbidities, and costs than temporary migraine headaches.

Eptinezumab is an FDA-approved calcitonin gene-related peptide antagonist for the prophylactic treatment of migraine. Treatment is given by intravenous drip once every 12 weeks.

“In the PROMISE-2 clinical trial, eptinezumab significantly reduced the frequency of migraine when administered to CM patients, showing a rapid onset of sustained prophylactic effect 24 hours after administration, with therapeutic benefits. The study was maintained for 6 months (2-dose) study, “the study authors write. “Eptinezumab treatment was also associated with significantly reduced outcome indicators of daily function reported by patients, including a significant reduction in acute drug use and a significant reduction in life-related effects associated with severe headaches (” 6-item headache effect test [HIT-6]And compared to placebo, the most annoying symptoms identified by the patient (patient-identified MBS) and overall health (impression of the patient’s global change) were significantly improved. “

PROMISE-2 is a double-blind, placebo-controlled, parallel-group study in which 1072 CM patients were randomized to receive eptinezumab 100 mg, 300 mg, or placebo intravenously every 12 weeks for up to 24 weeks. bottom. Migraine and non-migraine episodes and features were recorded by participants in the daily electronic diary during a 28-day baseline and a 24-week treatment period.

In 1072 patients, the mean monthly headache days decreased by 8.9 in the 100 mg cohort and 9.7 in the 300 mg cohort, but decreased by 7.3 in the first 4 weeks after the first dose in the placebo group. These reductions were maintained throughout the 24-week treatment period.

Mean monthly headache episodes decreased by 8.4 in the 100 mg cohort and 9.0 in the 300 mg cohort, compared to 7.1 in the placebo group. The percentage of migraine episodes decreased by 11.2% in the 100 mg cohort, 12.4% in the 300 mg cohort, and 3.9% in the placebo cohort.

The study also found that the reductions in severe pain, nausea, phonophobia, photophobia, and physical activity restriction were numerically greater than in the placebo group.

The study concluded that patients with CM treated with Eptinezumab experienced a reduction in the number of days of headache and the monthly severity and frequency of episodes compared to placebo.

“In addition to a reduction in the frequency of headaches, patients treated with Eptinezumab reported a reduction in the proportion of remaining headache episodes that were migraine attacks, and a reduction in the nasty symptoms of headache episodes, and headaches after treatment with Eptinezumab. Shows a further reduction in the severity of the headache. “

reference

McAllister P, Kudrow D, Caddy R, Hirman J, Ettrup A. Migraine-related burden reduction after Eptinezumab treatment in patients with chronic migraine. headache. March 25, 2022: 3331024221089567. Doi: 10.1177 / 03331024221089567. Epub before printing. PMID: 35332807.

ExBulletin

Eptinezumab was found to reduce the severity and frequency of migraine days